313 related articles for article (PubMed ID: 20211018)
1. Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
Bachawal SV; Wali VB; Sylvester PW
BMC Cancer; 2010 Mar; 10():84. PubMed ID: 20211018
[TBL] [Abstract][Full Text] [Related]
2. Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.
Bachawal SV; Wali VB; Sylvester PW
Anticancer Res; 2010 Feb; 30(2):429-37. PubMed ID: 20332450
[TBL] [Abstract][Full Text] [Related]
3. gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells.
Samant GV; Sylvester PW
Cell Prolif; 2006 Dec; 39(6):563-74. PubMed ID: 17109639
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.
Shirode AB; Sylvester PW
Biomed Pharmacother; 2010 May; 64(5):327-32. PubMed ID: 19954924
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1.
Wali VB; Bachawal SV; Sylvester PW
Exp Biol Med (Maywood); 2009 Jun; 234(6):639-50. PubMed ID: 19359655
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms mediating the synergistic anticancer effects of combined γ-tocotrienol and sesamin treatment.
Akl MR; Ayoub NM; Sylvester PW
Planta Med; 2012 Nov; 78(16):1731-9. PubMed ID: 22987298
[TBL] [Abstract][Full Text] [Related]
7. Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells.
Shah S; Sylvester PW
Exp Biol Med (Maywood); 2004 Sep; 229(8):745-55. PubMed ID: 15337828
[TBL] [Abstract][Full Text] [Related]
8. Endoplasmic reticulum stress mediates gamma-tocotrienol-induced apoptosis in mammary tumor cells.
Wali VB; Bachawal SV; Sylvester PW
Apoptosis; 2009 Nov; 14(11):1366-77. PubMed ID: 19771520
[TBL] [Abstract][Full Text] [Related]
9. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells.
Sylvester PW; Shah S
Asia Pac J Clin Nutr; 2005; 14(4):366-73. PubMed ID: 16326643
[TBL] [Abstract][Full Text] [Related]
10. Sesamin synergistically potentiates the anticancer effects of γ-tocotrienol in mammary cancer cell lines.
Akl MR; Ayoub NM; Abuasal BS; Kaddoumi A; Sylvester PW
Fitoterapia; 2013 Jan; 84():347-59. PubMed ID: 23266736
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells.
Wali VB; Sylvester PW
Lipids; 2007 Dec; 42(12):1113-23. PubMed ID: 17701065
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anticancer effects of combined γ-tocotrienol and oridonin treatment is associated with the induction of autophagy.
Tiwari RV; Parajuli P; Sylvester PW
Mol Cell Biochem; 2015 Oct; 408(1-2):123-37. PubMed ID: 26112904
[TBL] [Abstract][Full Text] [Related]
13. γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells.
Ayoub NM; Bachawal SV; Sylvester PW
Cell Prolif; 2011 Dec; 44(6):516-26. PubMed ID: 21973114
[TBL] [Abstract][Full Text] [Related]
14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
15. Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity.
Shah SJ; Sylvester PW
Exp Biol Med (Maywood); 2005 Apr; 230(4):235-41. PubMed ID: 15792944
[TBL] [Abstract][Full Text] [Related]
16. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
17. Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment.
Wali VB; Bachawal SV; Sylvester PW
Lipids; 2009 Oct; 44(10):925-34. PubMed ID: 19777282
[TBL] [Abstract][Full Text] [Related]
18. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
19. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
[TBL] [Abstract][Full Text] [Related]
20. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
